518 Rec'd PCT/PTO 0 6 AUG Custom**e**r

AUG 0 6.200

Attorney Docket No. 2037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Frédéric TRIEBEL et al.

1642

Group Art Unit: Not assigned

Application No.: 09/673,795

Examiner: Not assigned

Filed: October 20, 2000

For:

MUTATED PEPTIDE

COMPOUNDS, DERIVED FROM

hsp70, USEFUL IN CANCER

IMMUNOTHERAPY

Assistant Commissioner for Patents Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

Please substitute the paragraph located on page 19, lines 30-36, with the following paragraph:

FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L. L. P. 1300 I STREET, N. W. ASHINGTON, DC 20005

2000 cells transformed with EBV and labeled with ⁵¹Cr were incubated for 1 hour in the presence of the indicated hsp70-2 peptides (SEQ ID NOS. 2, 7, 1, and 8) at multiple concentrations. The 11C2 CTL was then added at an effector/target ratio (E/T)

19672795

0.00 (4 10 C 195 an ou